Cost of Revenue Comparison: AbbVie Inc. vs GSK plc

Cost of Revenue: A Tale of Two Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, AbbVie Inc. and GSK plc have showcased contrasting trends in their cost of revenue. From 2014 to 2023, AbbVie Inc. saw a staggering 361% increase, peaking in 2023. This growth reflects their aggressive expansion and investment in new therapies. In contrast, GSK plc's cost of revenue remained relatively stable, with a modest 17% increase over the same period, indicating a more conservative approach.

Key Insights

• AbbVie Inc.: From $4.4 billion in 2014 to $20.4 billion in 2023, AbbVie's cost of revenue highlights their strategic investments.
• GSK plc: Starting at $7.3 billion in 2014 and reaching $8.6 billion in 2023, GSK's steady trajectory suggests a focus on efficiency.
  These insights offer a glimpse into the strategic priorities of these pharmaceutical giants, shaping their future in the global market.